Дело T-***/**: *****************, Определение от **.**.2025 г.

Текст

... ursuant to Article 57(1)(n) of Regulation (EC) No 726/2004 – Decision to grant a third party access to the documents – Application for suspension of operation of a measure – No urgency )

In Case T‑666/24 R,

Teva Pharma BV, established in Haarlem (Netherlands), represented by C. Lindenthal and A. Säurig, lawyers,

applicant,

v

European Medicines Agency (EMA), represented by G. Gavriilidou, S. Drosos and G. Ramo, acting as Agents,

defendant,

THE PRESIDENT OF THE GENERAL COURT

having regard to the order of 30 December 2024, Teva Pharma v EMA (T‑666/24 R, not published),

makes the following

Order

1. By its application based on Articles 278 and 279 TFEU, the applicant, Teva Pharma BV, seeks suspension of the operation of Decision EMA/391476/2024 Rev.1 of the European Medicines Agency (EMA) of 28 October 2024 granting a third party, under Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to a document relating to scientific advice concerning the medicinal product ferric carboxymaltose, subject to certain redactions (‘the contested decision’).

Background to the dispute and forms of order sought

2. The applicant is a pharmaceutical company established in the Netherlands.

3. On 17 January 2020, the applicant requested scientific advice for the medicinal product ferric carboxymaltose (‘the medicinal product at issue’), a generic version of the medicinal product Ferinject, which is indicated for the treatment of iron deficiencies, pursuant ...